Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

Europe - FRA:1COV - DE0006062144 - Common Stock

60 EUR
-0.2 (-0.33%)
Last: 10/23/2025, 5:21:56 PM
Fundamental Rating

2

Overall 1COV gets a fundamental rating of 2 out of 10. We evaluated 1COV against 66 industry peers in the Chemicals industry. 1COV may be in some trouble as it scores bad on both profitability and health. 1COV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year 1COV has reported negative net income.
In the past year 1COV had a positive cash flow from operations.
In multiple years 1COV reported negative net income over the last 5 years.
1COV had a positive operating cash flow in each of the past 5 years.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

Looking at the Return On Assets, with a value of -2.86%, 1COV is doing worse than 69.70% of the companies in the same industry.
1COV has a Return On Equity of -6.14%. This is in the lower half of the industry: 1COV underperforms 71.21% of its industry peers.
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

1COV's Operating Margin has declined in the last couple of years.
1COV has a worse Gross Margin (14.09%) than 77.27% of its industry peers.
In the last couple of years the Gross Margin of 1COV has declined.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.09%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
1COV has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1COV has more shares outstanding
The debt/assets ratio for 1COV has been reduced compared to a year ago.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

1COV has an Altman-Z score of 2.35. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.35, 1COV perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
1COV has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
1COV's Debt to Equity ratio of 0.34 is fine compared to the rest of the industry. 1COV outperforms 62.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 2.35
ROIC/WACCN/A
WACC6.4%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

A Current Ratio of 1.39 indicates that 1COV should not have too much problems paying its short term obligations.
1COV's Current ratio of 1.39 is on the low side compared to the rest of the industry. 1COV is outperformed by 68.18% of its industry peers.
1COV has a Quick Ratio of 1.39. This is a bad value and indicates that 1COV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.74, 1COV is not doing good in the industry: 80.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.74
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

3

3. Growth

3.1 Past

1COV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.54%.
The Revenue has decreased by -1.98% in the past year.
Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%

3.2 Future

1COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.27% yearly.
1COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.72% yearly.
EPS Next Y-7.01%
EPS Next 2Y60.31%
EPS Next 3Y48.4%
EPS Next 5Y20.27%
Revenue Next Year-6.95%
Revenue Next 2Y-1.93%
Revenue Next 3Y-0.15%
Revenue Next 5Y0.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

1

4. Valuation

4.1 Price/Earnings Ratio

1COV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 74.14, which means the current valuation is very expensive for 1COV.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1COV indicates a slightly more expensive valuation: 1COV is more expensive than 68.18% of the companies listed in the same industry.
1COV is valuated expensively when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 74.14
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1COV indicates a slightly more expensive valuation: 1COV is more expensive than 66.67% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.26
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

1COV's earnings are expected to grow with 48.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.31%
EPS Next 3Y48.4%

0

5. Dividend

5.1 Amount

No dividends for 1COV!.
Industry RankSector Rank
Dividend Yield N/A

COVESTRO AG

FRA:1COV (10/23/2025, 5:21:56 PM)

60

-0.2 (-0.33%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30
Inst Owners25.07%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.34B
Revenue(TTM)13.84B
Net Income(TTM)-378000000
Analysts49.47
Price Target61.98 (3.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-681.03%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-139.31%
EPS beat(4)1
Avg EPS beat(4)-330.2%
Min EPS beat(4)-1222.75%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4314.94%
EPS beat(12)2
Avg EPS beat(12)-2882.46%
EPS beat(16)4
Avg EPS beat(16)-2161.83%
Revenue beat(2)0
Avg Revenue beat(2)-5.71%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-5.8%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)-4.5%
Revenue beat(8)0
Avg Revenue beat(8)-4.99%
Revenue beat(12)1
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-2.08%
PT rev (1m)-0.16%
PT rev (3m)-1.51%
EPS NQ rev (1m)-18.93%
EPS NQ rev (3m)-218.18%
EPS NY rev (1m)-31.72%
EPS NY rev (3m)-577.27%
Revenue NQ rev (1m)-4.92%
Revenue NQ rev (3m)-11.02%
Revenue NY rev (1m)-2.77%
Revenue NY rev (3m)-8.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 74.14
P/S 0.82
P/FCF N/A
P/OCF 14.96
P/B 1.84
P/tB 2.26
EV/EBITDA 16.26
EPS(TTM)-2.01
EYN/A
EPS(NY)0.81
Fwd EY1.35%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)4.01
OCFY6.68%
SpS73.2
BVpS32.56
TBVpS26.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.09%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA 2.39
Cap/Depr 88.46%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion 85.65%
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.74
Altman-Z 2.35
F-Score4
WACC6.4%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
EPS Next Y-7.01%
EPS Next 2Y60.31%
EPS Next 3Y48.4%
EPS Next 5Y20.27%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%
Revenue Next Year-6.95%
Revenue Next 2Y-1.93%
Revenue Next 3Y-0.15%
Revenue Next 5Y0.72%
EBIT growth 1Y-183.74%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year267.68%
EBIT Next 3Y84.36%
EBIT Next 5Y41.79%
FCF growth 1Y-126.73%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y-37.61%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%